{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:26Z","timestamp":1790665886355,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002010.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000}}],"reference-count":106,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002010.pub5","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T11:51:02Z","timestamp":1673351462000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bisphosphonates for osteoporosis in people with cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Tomas C","family":"Jeffery","sequence":"additional","affiliation":[{"name":"Emergency Department; Queensland Health; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B","family":"Chang","sequence":"additional","affiliation":[{"name":"Child Health Division; Menzies School of Health Research, Charles Darwin University; Darwin Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise S","family":"Conwell","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes; Queensland Children\u2019s Hospital; Brisbane Australia"},{"name":"Children's Health Queensland Clinical Unit, Greater Brisbane Clinical School, Medical School, Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"10.1002\/14651858.CD002010.pub5-BIB0001|cit1","first-page":"365","article-title":"Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation","volume":"Suppl 17","author":"Aris","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"3 part 1","key":"10.1002\/14651858.CD002010.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","article-title":"Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation","volume":"162","author":"Aris","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0003|cit3","first-page":"364","article-title":"Effect of pamidronate on bone biomarkers in post-transplant osteoporotic cystic fibrosis patients","volume":"Suppl 17","author":"Aris","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0004|cit4","first-page":"351","article-title":"Efficacy of alendronate in CF adults with low bone density","volume":"36 Suppl 25","author":"Aris","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.200307-1049OC","article-title":"Efficacy of alendronate in adults with cystic fibrosis with low bone density","volume":"169","author":"Aris","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0006|cit6","unstructured":"Randomized study of alendronate in adult patients with cystic fibrosis related osteoporosis clinicaltrials.gov\/show\/NCT00004489"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-2600(13)70064-X","article-title":"Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate","volume":"1","author":"Bianchi","year":"2013","journal-title":"Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0008|cit8","unstructured":"Treatment of low bone density in cystic fibrosis clinicaltrials.gov\/show\/NCT01812551"},{"issue":"S28","key":"10.1002\/14651858.CD002010.pub5-BIB0009|cit9","first-page":"353","article-title":"Zoledronate therapy for decreased bone density in adults with cystic fibrosis","volume":"40","author":"Boyle","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2265.2008.03434.x","article-title":"Intravenous zoledronate improves bone density in adults with cystic fibrosis","volume":"70","author":"Chapman","year":"2009","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/thorax.56.4.314","article-title":"Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis","volume":"56","author":"Haworth","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0012|cit12","first-page":"295","article-title":"Pamidronate increases axial bone density in cystic fibrosis patients","volume":"28 Suppl 19","author":"Haworth","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002010.pub5-BIB0013|cit13","first-page":"A67","article-title":"Intravenous pamidronate increases axial bone density in cystic fibrosis adults","volume":"54","author":"Haworth","year":"1999","journal-title":"Thorax"},{"issue":"9167","key":"10.1002\/14651858.CD002010.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(05)75096-0","article-title":"Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis [letter]","volume":"353","author":"Haworth","year":"1999","journal-title":"Lancet"},{"issue":"9142","key":"10.1002\/14651858.CD002010.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis [letter]","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD002010.pub5-BIB0016|cit16","first-page":"423","article-title":"Two-year multicenter, randomised, double-blind, placebo-controlled trial assessing the effect of weekly Risedronate on bone mineral density in adults with CF","volume":"45","author":"Haworth","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","article-title":"Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis","volume":"10","author":"Haworth","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002010.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(10)60328-1","article-title":"Multicentre randomised double blind placebo controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with cystic fibrosis","volume":"9","author":"Haworth","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0019|cit19","unstructured":"A randomised double blind placebo controlled trial assessing the effect of once weekly risedronate on bone mineral density in adults with cystic fibrosis www.isrctn.com\/ISRCTN36453336"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0020|cit20","unstructured":"Krasovsky S Baranova I Demin N Amelina E Efficacy of alendronate\/colecalciferol\/calcium in adults with cystic fibrosis European Respiratory Society Annual Congress; 2010 Sep 18-22; Barcelona, Spain 2010 698s"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0021|cit21","unstructured":"Study of alendronate to prevent and treat osteoporosis in cystic fibrosis patients clinicaltrials.gov\/show\/NCT00157690"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1378\/chest.08-0608","article-title":"Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)","volume":"134","author":"Papaioannou","year":"2008","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD002010.pub5-BIB0023|cit23","first-page":"270","article-title":"Oral bisphosphonates improve bone mineral density in adults with cystic fibrosis","volume":"98","author":"Cawood","year":"2005","journal-title":"Irish Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD002010.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2002.002568","article-title":"Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study","volume":"59","author":"Conway","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1515\/JPEM.2005.18.6.589","article-title":"Growth hormone improves bone mineral content in children with cystic fibrosis","volume":"18","author":"Hardin","year":"2005","journal-title":"Journal of Paediatric Endocrinology & Metabolism"},{"issue":"9142","key":"10.1002\/14651858.CD002010.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0027|cit27","unstructured":"Zoledronic acid in cystic fibrosis clinicaltrials.gov\/show\/NCT01702415"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0028|cit28","unstructured":"Assessment of response to treatment of osteoporosis with oral bisphosphonates in patients with muscular dystrophy clinicaltrials.gov\/ct2\/show\/NCT01882400"},{"issue":"12","key":"10.1002\/14651858.CD002010.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.arcped.2004.07.028","article-title":"Effect of oral biphosphonates in patients with cystic fibrosis and low bone mineral density","volume":"11","author":"Ringuier","year":"2004","journal-title":"Archives de P\u00e9diatrie"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","article-title":"Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment","volume":"44","author":"Rudge","year":"2005","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub5-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jcf.2013.11.001","article-title":"Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis","volume":"13","author":"Alicandro","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD002010.pub5-BIB0032|cit32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001347.pub2","article-title":"Bisphosphonates for steroid-induced osteoporosis","author":"Allen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2478\/ams-2013-0011","article-title":"Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis","volume":"58","author":"Ambroszkiewicz","year":"2013","journal-title":"Advances in Medical Sciences"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","article-title":"Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications","volume":"18 Suppl 2","author":"Anabtawi","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1378\/chest.109.5.1176","article-title":"Severe osteoporosis before and after lung transplantation","volume":"109","author":"Aris","year":"1996","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub5-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1359\/JBMR.051106","article-title":"BMD and body composition in children and young patients affected by cystic fibrosis","volume":"21","author":"Bianchi","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9041","key":"10.1002\/14651858.CD002010.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.mcp.0000245708.59138.a4","article-title":"Update on maintaining bone health in cystic fibrosis","volume":"12","author":"Boyle","year":"2006","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/thorax.2003.006726","article-title":"Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study","volume":"59","author":"Buntain","year":"2004","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/thx.2005.046516","article-title":"Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis","volume":"61","author":"Buntain","year":"2006","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00198-019-04893-z","article-title":"Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure","volume":"30","author":"Cairoli","year":"2019","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0043|cit43","first-page":"18","article-title":"Prevalence of bone mineral disease among adolescents with cystic fibrosis","volume":"84","author":"Caldeira","year":"2008","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0044|cit44","unstructured":"Visual Rx. Online NNT calculator Cates C 2003"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-020-05327-x","article-title":"Exposure to oral bisphosphonates and risk of gastrointestinal cancer","volume":"31","author":"Choi","year":"2020","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD002010.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD002010.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2017.01.024","article-title":"The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide","volume":"104","author":"Curtis","year":"2017","journal-title":"Bone"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0050|cit50","unstructured":"Cystic Fibrosis Foundation Patient Registry 2018 Annual Report; 2019 Available at www.cff.org\/medical-professionals\/patient-registry"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatrica"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jped.2013.03.008","article-title":"Bone mineral density, pulmonary function, chronological age, and age at diagnosis in children and adolescents with cystic fibrosis","volume":"89","author":"Donadio","year":"2013","journal-title":"Jornal de Pediatria"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"611921","DOI":"10.3389\/fcell.2021.611921","article-title":"Bone cells differentiation: how CFTR mutations may rule the game of stem cells commitment?","volume":"9","author":"Dumortier","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"10","key":"10.1002\/14651858.CD002010.pub5-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12969-020-0411-9","article-title":"Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children","volume":"18","author":"Galindo-Zavala","year":"2020","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2013.01.032","article-title":"Biomedical applications of bisphosphonates","volume":"167","author":"Giger","year":"2013","journal-title":"Journal of Controlled Release"},{"issue":"14","key":"10.1002\/14651858.CD002010.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0058|cit58","first-page":"926045","article-title":"A roadmap to the brittle bones of cystic fibrosis","volume":"2011","author":"Gore","year":"2010","journal-title":"Journal of Osteoporosis"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"Journal of Cellular Biochemistry"},{"issue":"7","key":"10.1002\/14651858.CD002010.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s13312-017-1065-7","article-title":"Bone mineral density of Indian children and adolescents with cystic fibrosis","volume":"54","author":"Gupta","year":"2017","journal-title":"Indian Pediatrics"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"218691","DOI":"10.1155\/2010\/218691","article-title":"Vitamin D deficiency in cystic fibrosis","volume":"2010","author":"Hall","year":"2010","journal-title":"International Journal of Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/MCP.0b013e32833e2e94","article-title":"Impact of cystic fibrosis on bone health","volume":"16","author":"Haworth","year":"2010","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1378\/chest.11-0132","article-title":"Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis","volume":"140","author":"Hayes","year":"2011","journal-title":"Chest"},{"issue":"7414","key":"10.1002\/14651858.CD002010.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0065|cit65","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jbspin.2010.11.015","article-title":"Bone disease in cystic fibrosis: what's new?","volume":"78","author":"Javier","year":"2011","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"117955141985177","DOI":"10.1177\/1179551419851770","article-title":"Cystic fibrosis-related diabetes: pathophysiology and therapeutic challenges","volume":"12","author":"Kelsey","year":"2019","journal-title":"Clinical Medicine Insights. Endocrinology and Diabetes"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/medicina56060302","article-title":"Risk factors and management of osteoporosis post-transplant","volume":"56","author":"Kovvuru","year":"2020","journal-title":"Medicina"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jbspin.2011.05.009","article-title":"Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers","volume":"79","author":"Legroux-Gerot","year":"2012","journal-title":"Joint, Bone, Spine"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2009.11.005","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone","volume":"9","author":"Le Heron","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"175346661988007","DOI":"10.1177\/1753466619880078","article-title":"Lung transplantation: a review of the optimal strategies for referral and patient selection","volume":"13","author":"Mitchell","year":"2019","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-020-05498-7","article-title":"Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients","volume":"32","author":"Nguyen","year":"2021","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bone.2017.11.006","article-title":"Adults with cystic fibrosis have deficits in bone structure and strength at the distal tibia despite similar size and measuring standard and relative sites","volume":"107","author":"Nishiyama","year":"2018","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MCP.0b013e3283659e35","article-title":"Cystic fibrosis-related bone disease","volume":"19","author":"Paccou","year":"2013","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11914-008-0006-8","article-title":"Osteonecrosis of the jaws and bisphosphonates","volume":"6","author":"Pendrys","year":"2008","journal-title":"Current Osteoporosis Reports"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18 Suppl 2","author":"Putman","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"Journal of Translational Medicine"},{"issue":"25","key":"10.1002\/14651858.CD002010.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0080|cit80","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"RIsks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub5-BIB0082|cit82","first-page":"e20170280","article-title":"Evaluation of bone disease in patients with cystic fibrosis and end stage lung disease","volume":"45","author":"Robinson","year":"2019","journal-title":"Brazilian Journal of Pulmonology"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cld.2018.12.008","article-title":"Hepatic manifestations of cystic fibrosis","volume":"23","author":"Sakiani","year":"2019","journal-title":"Clinics in Liver Disease"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ocl.2013.01.001","article-title":"Bisphosphonate therapy and atypical fractures","volume":"44","author":"Saleh","year":"2013","journal-title":"Orthopedic Clinics of North America"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0089|cit89","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P et al on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes"},{"issue":"9","key":"10.1002\/14651858.CD002010.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1164\/rccm.200606-776OC","article-title":"Low bone mineral density in young children with cystic fibrosis","volume":"175","author":"Sermet-Gaudelus","year":"2007","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10 Suppl 2","author":"Sermet-Gaudelus","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2009.11.007","article-title":"Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis","volume":"9","author":"Shead","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.jcf.2019.08.019","article-title":"Endocrine complications after solid-organ transplant in cystic fibrosis","volume":"18 Suppl 2","author":"Sidhaye","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"12","key":"10.1002\/14651858.CD002010.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/ppul.23894","article-title":"Bone mineral density is related to lung function outcomes in young people with cystic fibrosis - a retrospective study","volume":"52","author":"Smith","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD002010.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"e80098","DOI":"10.1371\/journal.pone.0080098","article-title":"Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease","volume":"8","author":"Stalvey","year":"2013","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","article-title":"Cystic fibrosis-related bone disease: insights into a growing problem","volume":"20","author":"Stalvey","year":"2013","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Current Osteoporosis Reports"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.1997.00586.x","article-title":"Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression","volume":"43","author":"Steer","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"125705","DOI":"10.1155\/2013\/125705","article-title":"The role of inflammatory cytokines, the RANKL\/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis","volume":"2013","author":"Weitzmann","year":"2013","journal-title":"Scientifica"},{"key":"10.1002\/14651858.CD002010.pub5-BIB0102|cit102","volume-title":"Cystic Fibrosis in Adults","author":"Yankaskas","year":"1999"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub2","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Brenckmann","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub2","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Conwell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub5-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub3","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Conwell","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub5-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub4","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Conwell","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T03:48:55Z","timestamp":1769399335000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002010.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002010.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}